ReviewJournal of clinical and experimental hepatology
Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Review
- Prognostic Value of the TLM3 Biomarker Panel for Early Fibrosis Development in MASLD Within the General Population.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials.International journal of translational medicine (Basel, Switzerland) · 2025Article
- Challenges ofFrontiers in cell and developmental biology · 2025Review
- Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives.International journal of pharmaceutics · 2024Review
- Effect of exercise and pharmacotherapy on non-alcoholic fatty liver disease.SAGE open medicine · 2024Article
- Non-alcoholic fatty liver disease: the pathologist's perspective.Clinical and molecular hepatology · 2023Review
- Preclinical Long-term Magnetic Resonance Imaging Study of Silymarin Liver-protective Effects.Journal of clinical and translational hepatology · 2022Article
- CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice.International journal of molecular sciences · 2022Article
- Article
- State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis.Endocrinology and metabolism (Seoul, Korea) · 2022Review
- Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models.Antioxidants (Basel, Switzerland) · 2021Review
- Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity.World journal of hepatology · 2021Review
- Lean NAFLD: an underrecognized and challenging disorder in medicine.Reviews in endocrine & metabolic disorders · 2021Review
- Triantennary GalNAc Molecular Imaging Probes for Monitoring Hepatocyte Function in a Rat Model of Nonalcoholic Steatohepatitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination.Scientific reports · 2020Article
- Carbon tetrachloride (CClBMC gastroenterology · 2020Article
- Ethyl Acetate Fraction ofNutrients · 2020Article
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review.Endocrinology, diabetes & metabolism · 2020Review
- β-Hydroxybutyrate is reduced in humans with obesity-related NAFLD and displays a dose-dependent effect on skeletal muscle mitochondrial respiration in vitro.American journal of physiology. Endocrinology and metabolism · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease in industrialized economies. With no licensed treatment currently available, together with a growing prevalence that parallels global increases in obesity and type 2 diabetes, NAFLD will dominate the landscape of hepatology for the foreseeable future. A multifaceted etiopathogenesis, paucity of reproducible preclinical models that effectively recreate human NAFLD, and lack of robust surrogate trial endpoints have presented major hurdles in drug discovery and development. Smooth collaboration between bench scientists, biotechnology, pharmaceutical industries, and clinicians will be pivotal to target identification, development of effective therapies, biomarker discovery, and ultimately to bring pipeline drugs to market. This review examines the key challenges remaining in NAFLD drug development, outlines early and late phase clinical trials of candidate treatments, and discusses the journey toward biomarker discovery which may facilitate development of novel endpoints in NAFLD clinical trials, enabling meaningful response to be determined noninvasively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.